Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01666444
What this trial is testing

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Celgene 297
Testing effectiveness (Phase 2)Ended earlyNCT02923739
What this trial is testing

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+17 more
M.D. Anderson Cancer Center 9
Testing effectiveness (Phase 2)UnknownNCT00838656
What this trial is testing

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Warwick Medical School 88
Testing effectiveness (Phase 2)Study completedNCT01146795
What this trial is testing

Neoadjuvant Therapy for Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Jason D. Wright 32
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Early research (Phase 1)Study completedNCT00055705
What this trial is testing

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Not applicableNot Yet RecruitingNCT07687602
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

Who this might be right for
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian CancerFolate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube CancerFolate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
AbbVie
Early research (Phase 1)Ended earlyNCT02452775
What this trial is testing

Autologous OC-L Vaccine and Ovarian Cancer

Who this might be right for
Primary Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine 3
Testing effectiveness (Phase 2)Study completedNCT01899599
What this trial is testing

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Who this might be right for
Ovarian Epithelial Cancer RecurrentFallopian Tube CancerPrimary Peritoneal Cancer
Glycotope GmbH 216
Large-scale testing (Phase 3)Not Yet RecruitingNCT07797283
What this trial is testing

Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

Who this might be right for
Ovarian Cancer
Incyte Corporation 590
Early research (Phase 1)Study completedNCT00989651
What this trial is testing

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+35 more
National Cancer Institute (NCI) 431
Not applicableEnded earlyNCT03412630
What this trial is testing

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Study completedNCT00182767
What this trial is testing

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Who this might be right for
Fallopian Tube CancerFemale Reproductive CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT02606305
What this trial is testing

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
ImmunoGen, Inc. 264
Testing effectiveness (Phase 2)Study completedNCT01720173
What this trial is testing

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Gynecologic Oncology Group 30
Testing effectiveness (Phase 2)Study completedNCT00671788
What this trial is testing

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Gynecologic Oncology Group 35
Large-scale testing (Phase 3)Ended earlyNCT01281254
What this trial is testing

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 223
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Not applicableUnknownNCT00897039
What this trial is testing

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Southeastern Gynecologic Oncology 60
Not applicableLooking for participantsNCT03862677
What this trial is testing

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
Leiden University Medical Center 300
Next Page
69